MERERA THERAPEUTICS · GENEVA
Pioneering precision-engineered therapeutics to expand women’s reproductive choices.
01 / OUR MISSION
Women have gained greater freedom to decide when to pursue education, careers, relationships and motherhood. Yet female reproductive ageing continues to impose biological constraints on those choices.
At MERERA Therapeutics, our mission is to develop innovative treatments that address age-related declines in egg quality, with the goal of improving IVF outcomes using women’s own oocytes.
We aim to make genetic motherhood a possibility for more women, including those who currently face repeated unsuccessful IVF cycles or the prospect of donor eggs.
02 / OUR SCIENCE
Addressing age-related infertility at its biological source.
Age-related decline in oocyte quality is driven in part by chromosome segregation errors during meiosis, contributing to aneuploidy and reduced reproductive potential.
MERERA is developing precision-engineered protein therapeutics designed to preserve chromosome integrity during oocyte maturation. Our approach aims to address the underlying biology of egg quality, rather than focusing solely on ovarian stimulation or embryo selection.
Preclinical research. Functional efficacy and clinical benefit have not yet been established.
03 / FOUNDING TEAM
Founding Team
A founding team dedicated to advancing the science of women’s reproductive health.
Dr Sanja Fitzgerald
Co-Founder & CEO
PhD, ETH Zurich. 17+ years across scientific innovation, pharmaceutical strategy, market access and commercialization. Leads corporate strategy, partnerships and development.
Dr Daniel Fitzgerald
Co-Founder & CTO
Protein engineering expert with 20+ years of experience in recombinant protein technologies. Co-developer of MultiBac. Leads therapeutic engineering and development.
Prof. Imre Berger
Co-Founder & CSO
Internationally recognized scientist in structural biology and multiprotein engineering. Co-developer of MultiBac. Leads scientific strategy.
04 / PARTNERSHIPS & CONTACT
Advancing reproductive science together.
We welcome discussions with academic researchers, biotechnology and pharmaceutical partners, and investors interested in advancing innovative treatments for age-related infertility.
Contact: sanja.fitzgerald@sur-access.com
MERERA Therapeutics
Geneva, Switzerland · © 2026 MERERA Therapeutics